Ionis Pharmaceuticals (IONS) Long-Term Deferred Tax (2012 - 2020)

Ionis Pharmaceuticals' Long-Term Deferred Tax history runs 5 years deep, the most recent figure standing at $307.7 million for Q3 2020.

• In Q3 2020, Long-Term Deferred Tax rose 7.98% year-over-year to $307.7 million; the TTM figure through Sep 2020 stood at $307.7 million (up 7.98% YoY), while the FY2019 annual figure was $305.6 million, up 5.08% from the prior year.
• Long-Term Deferred Tax for Q3 2020 stood at $307.7 million, up from $306.0 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $309.6 million in Q1 2020, with the low at $276.4 million in Q2 2019.
• The 3-year median for Long-Term Deferred Tax is $298.2 million (2018), against an average of $294.8 million.
• The sharpest annual moves came in 2019 and 2020: Long-Term Deferred Tax climbed 5.08% in 2019, then advanced 11.67% in 2020.
• Ionis Pharmaceuticals' Long-Term Deferred Tax stood at $290.8 million in 2018, then rose by 5.08% to $305.6 million in 2019, then increased by 0.71% to $307.7 million in 2020.
• Business Quant data shows IONS's Long-Term Deferred Tax at $307.7 million in Q3 2020, $306.0 million in Q2 2020, and $309.6 million in Q1 2020.